Fig. 1 · Structure

Documents & Downloads

Cyanidin chloride

Cat. No. A12201 CAS 528-58-5
Cyanidin chloride is an anthocyanin polyphenolic antioxidant compound with demonstrated cell protectant effects.

In Stock

Publications for Cyanidin chloride

1 publication citing this product

  1. Oluwatosin Popoola, .et al. , ACS Appl Mater Interfaces, 2024, Nov 6;16(44):60920-60932 PMID: 39436980

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Cyanidin chloride (A18) inhibited purified human IL-17A binding to IL-17RA–Fc, with a reported IC50 of 1.68 μM in a plate-based binding assay. IL-17E/IL-17RB and IL-17C/IL-17RE binding were less efficiently inhibited under the tested conditions. This IC50 describes ligand-receptor binding inhibition in that assay. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cyanidin chloride Research Summary

This section summarizes 2 in vitro studies and 1 in vivo study of Cyanidin chloride from 2 published references.

Cyanidin chloride In Vitro Studies

At 10 μM, cyanidin chloride reduced biotinylated IL-17A binding to IL-17RA-expressing HEK 293 cells and to HeLa cells, assessed by flow cytometry with PBS and anti-IL-17A antibody controls. The reported distributions demonstrate a cellular binding effect; they do not establish a viability margin. [1]

Inhibition of purified IL-17A–IL-17RA binding

Biochemical assay · Purified human IL-17A/IL-17RA–Fc ligand-receptor assay; IL-17E/IL-17RB–Fc and IL-17C/IL-17RE–Fc comparator pairs [1]

A18 inhibited IL-17A/IL-17RA binding with a reported IC50 of 1.68 μM. Comparator receptor-ligand pairs were less efficiently inhibited, rather than completely unaffected at every tested concentration. Figure 1 reports means ± SEM from three independent experiments; DMSO control binding was set to 100%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of human IL-17A/IL-17RA–Fc bindingIC50 1.68 μM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Serial A18 dilutions; the reported IC50 is an assay endpoint, not a treatment regimen.
Exposure duration
Methods describe 1 h receptor incubation followed by 1 h HRP-conjugated anti-Fc incubation in the presence or absence of A18.
Method
Ligand-coated plates; IL-17 ligands 2 μg/mL and corresponding receptor-Fc proteins 150 ng/mL, as reported in the shared method.
Vehicle
DMSO control in Figure 1 caption
Reported limits
No IC50 uncertainty interval is reported with the stated value. The IC50 is specific to this assay.
Methods and source locations

Compound reported in the paper: Cyanidin chloride; Compound label in the paper: A18

Published experiments used another supplier’s cyanidin chloride; they do not validate an Adooq lot.

Figure 1B, 1E–G and caption; Results, A18 specifically inhibits the binding of IL-17A to IL-17RA; Methods, Compounds and Ligand-receptor binding inhibition assay

Inhibition of human IL-17A/IL-17RA–Fc binding: Plate-based ligand-receptor binding assay with HRP-conjugated anti-Fc detection and tetramethylbenzidine substrate; Figure 1E and Results provide the IC50. — Figure 1B, 1E–G and caption; Results, A18 specifically inhibits the binding of IL-17A to IL-17RA; Methods, Compounds and Ligand-receptor binding inhibition assay

Reduced IL-17A binding to live human cells

Cell-based study · HEK 293 cells stably expressing IL-17RA and HeLa cells with endogenous receptors [1]

At 10 μM, A18 reduced the flow-cytometric binding signal of biotinylated IL-17A in both cell models. PBS and an anti-human IL-17A antibody served as negative and positive controls, respectively. Figure 2A presents representative distributions from three experiments; no exact percentage inhibition is extracted.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell-associated biotinylated IL-17A signalQualitative flow-cytometric comparison Reduced binding signal with A18 in both reported cell models[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM A18
Method
Cells were exposed to biotinylated IL-17A with PBS, A18 or anti-human IL-17A antibody, then stained with avidin-fluorescein.
Vehicle
PBS is identified as the negative control for this assay.
Co-treatment
Biotinylated IL-17A is the binding probe; anti-IL-17A antibody is a separate positive-control condition.
Reported limits
The cited binding method does not specify ligand concentration or exposure duration. This binding readout is not a viability or clinical-efficacy endpoint.
Methods and source locations

Compound reported in the paper: Cyanidin chloride; Compound label in the paper: A18

Published experiments used another supplier’s cyanidin chloride; they do not validate an Adooq lot.

Figure 2A and caption; Results, A18 specifically inhibits IL-17A-induced gene expression in human and mouse cells (first paragraph); Methods, Compounds and Ligand-receptor binding inhibition assay

Cell-associated biotinylated IL-17A signal: Biotinylated IL-17A binding followed by avidin-fluorescein staining and flow cytometry. — Figure 2A and caption; Results, A18 specifically inhibits IL-17A-induced gene expression in human and mouse cells (first paragraph); Methods, Compounds and Ligand-receptor binding inhibition assay

Cyanidin chloride In Vivo Studies

In an acute ethanol-induced gastric-lesion model, oral cyanidin chloride pretreatment reduced lesion area in male mice at 5–20 mg·kg−1 and in estradiol-supplemented ovariectomized females at 20 mg·kg−1. Unsupplemented ovariectomized females showed no significant protection at the tested doses. The response depended on the reported model and hormonal condition; these experiments assessed prevention rather than ulcer healing. [2]

Sex and hormonal context in acute gastric-lesion prevention

Animal study · Male and ovariectomized female Swiss mice, with or without estradiol supplementation, challenged with absolute ethanol [2]

Oral cyanidin pretreatment reduced macroscopic gastric lesion area at all tested doses in males and at 20 mg·kg−1 in estradiol-supplemented ovariectomized females. No significant macroscopic protection was shown in unsupplemented ovariectomized females. These are acute lesion-prevention findings, not ulcer-healing or human treatment evidence. Figure 3 reports mean ± SEM and ANOVA/Dunnett comparisons; precise per-group n is unclear because plotted point counts differ from the methods statement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Macroscopic gastric lesion area after ethanol challenge, stratified by sex/hormonal conditionDirection of lesion-area response Male: lower at 5, 10, 20 mg·kg−1; estradiol-supplemented OVX female: lower at 20 mg·kg−1; unsupplemented OVX female: no significant reduction at tested doses.[2]

Conditions shared by the study groups

Route
Oral
Frequency
Once for cyanidin
Vehicle
0.9% saline vehicle comparator
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Male Swiss mice
5, 10 and 20 mg·kg−1
Corresponding vehicle-treated, ethanol-challenged group; lansoprazole 30 mg·kg−1 was a separate positive comparator.All three tested doses reduced macroscopic lesion area versus vehicle in Figure 3A.[2]
Ovariectomized female Swiss mice receiving estradiol supplementation
5, 10 and 20 mg·kg−1
Corresponding vehicle-treated, ethanol-challenged group; lansoprazole 30 mg·kg−1 was a separate positive comparator.The 20 mg·kg−1 cyanidin condition reduced lesion area; 5 and 10 mg·kg−1 did not show significant protection versus the corresponding vehicle in Figure 3B.[2]
Ovariectomized female Swiss mice without estradiol supplementation
5, 10 and 20 mg·kg−1
Corresponding vehicle-treated, ethanol-challenged group; lansoprazole 30 mg·kg−1 was a separate positive comparator.No tested cyanidin dose showed significant reduction of lesion area versus vehicle in Figure 3C.[2]
Male Swiss mice
Model: Male Swiss mice
Treatment course: Single oral pretreatment
Reported limits: Methods 2.2.5 states n = 5, while some Figure 3 groups visibly contain six points; exact per-group sample sizes remain unclear.
Ovariectomized female Swiss mice receiving estradiol supplementation
Model: Ovariectomized female Swiss mice receiving estradiol supplementation
Treatment course: Single oral cyanidin pretreatment; background oral estradiol-3-benzoate 500 μg/kg for 14 days
Reported limits: Methods 2.2.5 states n = 5, while some Figure 3 groups visibly contain six points; exact per-group sample sizes remain unclear.
Ovariectomized female Swiss mice without estradiol supplementation
Model: Ovariectomized female Swiss mice without estradiol supplementation
Treatment course: Single oral pretreatment
Reported limits: Methods 2.2.5 states n = 5, while some Figure 3 groups visibly contain six points; exact per-group sample sizes remain unclear.
Methods and source locations

Compound reported in the paper: Cyanidin chloride; Compound label in the paper: Cyd

Results apply to the reported Cayman material and mouse conditions; no Adooq lot equivalence was tested.

Sections 2.1, 2.2.1–2.2.6 and 3.1.1; Figure 3A–C and caption

Macroscopic gastric lesion area after ethanol challenge, stratified by sex/hormonal condition: Macroscopic lesion-area evaluation; Figure 3 and Results 3.1.1. Qualitative directions only; no curve-derived decimals. — Sections 2.1, 2.2.1–2.2.6 and 3.1.1; Figure 3A–C and caption

Male Swiss mice · Sections 2.1, 2.2.1–2.2.6 and 3.1.1; Figure 3A–C and caption

Ovariectomized female Swiss mice receiving estradiol supplementation · Sections 2.1, 2.2.1–2.2.6 and 3.1.1; Figure 3A–C and caption

Ovariectomized female Swiss mice without estradiol supplementation · Sections 2.1, 2.2.1–2.2.6 and 3.1.1; Figure 3A–C and caption

Specifications

Manufacturer Adooq Bioscience
CAS Number 528-58-5
Formula C15H11ClO6
Molecular Weight 322.7
SMILES
C1=CC(=C(C=C1C2=C(C=C3C(=CC(=CC3=[O+]2)O)O)O)O)O.[Cl-]

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cyanidin chloride Research References

  1. [1] Caini Liu, Liang Zhu, Koichi Fukuda, et al. The flavonoid cyanidin blocks binding of the cytokine interleukin-17A to the IL-17RA subunit to alleviate inflammation in vivo Science signaling (2017). PMID: 28223414 DOI: 10.1126/scisignal.aaf8823 Source material
  2. [2] Melina Luzzi Zarricueta, Felipe Leonardo Fagundes, Quélita Cristina Pereira, et al. Relationship between Hormonal Modulation and Gastroprotective Activity of Malvidin and Cyanidin Chloride: In Vivo and In Silico Approach Pharmaceutics (2022). PMID: 35335941 DOI: 10.3390/pharmaceutics14030565 Source material

Publications

1 publication citing this product

  1. Oluwatosin Popoola, .et al. , ACS Appl Mater Interfaces, 2024, Nov 6;16(44):60920-60932 PMID: 39436980

Added to your cart

View Cart Checkout
Loading...